Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Cost of Revenue for 7 consecutive years, with $12.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 5.16% year-over-year to $12.5 million; the trailing twelve-month figure through Jun 2026 stood at $45.0 million (up 3.05% YoY), and the FY2025 full-year result was $42.6 million, up 15.58% from the prior year.
• Cost of Revenue improved to $12.5 million in Q2 2026 per XERS's latest filing, from $10.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.6 million in Q3 2024 and bottomed at $4.8 million in Q2 2022.
• Historically, Cost of Revenue has averaged $8.5 million across 5 years, with a median of $8.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue jumped 243.54% in 2022, then decreased 19.11% in 2025.
• Over 5 years, Cost of Revenue stood at $6.3 million in 2022, then grew by 20.33% to $7.6 million in 2023, then climbed by 25.2% to $9.5 million in 2024, then advanced by 15.5% to $10.9 million in 2025, then increased by 14.3% to $12.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $12.5 million, $10.6 million, and $10.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.